www.idosr.org Niwarinda
©IDOSR PUBLICATIONS ISSN: 2550-794X
International Digital Organization for Scientific Research IDOSRJSR10.300000
IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(3):33-36, 2025.
https://doi.org/10.59298/IDOSRJSR/2024/10.3.3336

SGLT2 Inhibitors in Type 2 Diabetes Management: Renal Protection and Cardiovascular Outcomes

Niwarinda Arnold

Department of Pharmacy Kampala International University Uganda
Email: arnold.niwarinda@studwc.kiu.ac.ug

ABSTRACT

Type 2 diabetes mellitus (T2DM) is a major driver of cardiovascular and renal morbidity worldwide. Despite advances in glucose-lowering therapies, patients remained at elevated risk for chronic kidney disease (CKD) and cardiovascular events, underscoring the need for therapeutic agents that provide benefits beyond glycemic control. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have emerged as disease-modifying agents with renoprotective and cardioprotective properties. This review critically evaluated the clinical and mechanistic evidence for SGLT2 inhibitors in renal protection and cardiovascular outcomes in T2DM. This review synthesized peer-reviewed studies from PubMed, Scopus, and Web of Science databases, focusing on preclinical, pharmacokinetic, and randomized clinical trial reports published between 2010 and 2025. Large cardiovascular outcome trials such as EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, and DAPA-CKD consistently demonstrated significant reductions in major adverse cardiovascular events (MACE), hospitalization for heart failure, and progression of kidney disease with SGLT2i therapy. Empagliflozin reduced cardiovascular mortality by 38%, while dapagliflozin reduced CKD progression risk by 39%. Proposed mechanisms include improved tubuloglomerular feedback, reduced intraglomerular pressure, osmotic diuresis, natriuresis, and modulation of inflammatory pathways. Pharmacokinetic profiles revealed rapid absorption (tmax 1–2 hours) and half-lives supporting once-daily dosing. Safety profiles were favorable, though genital infections and rare diabetic ketoacidosis require monitoring. SGLT2 inhibitors provided robust renal and cardiovascular protection in T2DM, shifting treatment paradigms toward cardiorenal risk reduction. Future directions emphasized precision medicine, combination therapy, and expanded indications in non-diabetic kidney and heart disease.

Keywords: Type 2 diabetes, SGLT2 inhibitors, Renal protection, Cardiovascular outcomes, Pharmacotherapy.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) affects 537 million adults globally, a number projected to reach 783 million by 2045 [1]. Cardiovascular disease (CVD) accounts for over 50% of deaths in T2DM, while diabetic kidney disease (DKD) develops in up to 40% of patients, representing the leading cause of end-stage kidney disease (ESKD) worldwide [2]. Despite improved glycemic control strategies, residual cardiorenal risk remains alarmingly high. For example, in the ADVANCE trial, strict glycemic control reduced nephropathy by only 21%, underscoring the need for therapies with direct cardiorenal benefits [3].

Conventional treatments such as renin–angiotensin system (RAS) blockade have slowed but not eliminated CKD progression. Recent evidence highlights sodium–glucose cotransporter 2 inhibitors (SGLT2i) as transformative agents that extend beyond glucose lowering to provide clinically significant renal and cardiovascular protection [4]. Originally developed as antihyperglycemic agents, SGLT2i inhibit glucose reabsorption in the proximal tubule, promoting glucosuria. However, outcome trials revealed unexpected benefits in reducing hospitalization for heart failure and slowing CKD progression, even in non-diabetic populations [5].

Natural product–derived antidiabetic agents remain important in resource-limited settings [6,7], but SGLT2i exemplify the new generation of evidence-based synthetic therapies that combine metabolic control with organ protection. Preclinical studies demonstrate reductions in oxidative stress and inflammation, while clinical data show reductions in both MACE and renal endpoints [8]. This review synthesizes the pharmacological basis, renal and cardiovascular outcome data, mechanistic insights, and safety profiles of SGLT2i. It further evaluates clinical trial

evidence, real-world data, and emerging directions including combination therapies and applications beyond T2DM. The purpose is to provide researchers and clinicians with an updated, critical understanding of the role of SGLT2i in managing T2DM, with emphasis on renal protection and cardiovascular outcomes.

Pharmacological Basis of SGLT2 Inhibition

SGLT2 transporters, located in the S1 segment of the renal proximal tubule, reabsorb approximately 90% of filtered glucose [9]. Inhibition of SGLT2 reduces renal glucose reabsorption, promoting glucosuria and lowering plasma glucose independently of insulin secretion.

Pharmacokinetic studies demonstrate rapid absorption with peak plasma concentration (tmax) of 1–2 hours and half-lives (t1/2) of 10–17 hours, enabling once-daily dosing [10]. Bioavailability is high, and renal excretion accounts for a significant fraction of clearance. Importantly, efficacy persists even with declining renal function, though glucose-lowering capacity diminishes in advanced CKD [11].

Beyond glycemic control, SGLT2i induce osmotic diuresis, natriuresis, and modest weight loss (2–3 kg) and blood pressure reduction (3–5 mmHg), contributing to their cardiovascular and renal benefits [12].

Renal Protection

i. **Clinical Trial Evidence:** The renoprotective effects of SGLT2i are now well established. In EMPA-REG OUTCOME, empagliflozin reduced incident or worsening nephropathy by 39% and the risk of doubling of serum creatinine by 44% [13]. CANVAS reported a 40% reduction in albuminuria progression with canagliflozin [14]. In CREDENCE, canagliflozin reduced the risk of ESKD, doubling of serum creatinine, or renal death by 30% in patients with established DKD [15]. DAPA-CKD extended findings to non-diabetic CKD, reducing risk of renal decline or death from kidney disease by 39% [16].

ii. **Mechanisms:** Renoprotective mechanisms include improved tubuloglomerular feedback, reduced intraglomerular hypertension, decreased albuminuria, and attenuation of inflammatory and fibrotic pathways [17]. SGLT2i also reduce renal hypoxia by lowering proximal tubular workload and oxygen consumption [18].

Cardiovascular Outcomes

i. **Major Adverse Cardiovascular Events (MACE):** EMPA-REG OUTCOME demonstrated a 14% reduction in MACE with empagliflozin, driven by a 38% reduction in cardiovascular death [19]. CANVAS showed a 14% reduction in MACE with canagliflozin [20]. DECLARE-TIMI 58 reported a neutral MACE effect but a significant 27% reduction in hospitalization for heart failure [21].

ii. **Heart Failure:** Meta-analyses confirm consistent reductions in heart failure hospitalization across SGLT2i trials, with relative risk reductions of 30–35% [22]. Benefits are seen in patients with and without baseline heart failure, suggesting class effects beyond glycemic control [23].

iii. **Proposed Mechanisms:** Cardioprotective mechanisms include osmotic diuresis, preload and afterload reduction, improved myocardial energetics via ketone utilization, reduced oxidative stress, and modulation of neurohormonal signaling [24].

iv. **Safety Profile:** SGLT2i are generally well tolerated. The most common adverse events are genital mycotic infections, occurring in 5–10% of patients, and volume depletion events [25]. Euglycemic diabetic ketoacidosis (DKA) is rare but requires vigilance, particularly during illness or perioperative periods [26]. Initial concerns about fracture risk with canagliflozin were not confirmed in later studies [27]. Long-term safety data up to seven years remain reassuring [28].

v. **Comparative Efficacy:** Head-to-head comparisons are limited, but indirect evidence suggests class-wide renal and cardiovascular benefits. Empagliflozin is most robustly associated with cardiovascular mortality reduction, while dapagliflozin shows strong evidence in CKD progression across diabetic and non-diabetic patients [29]. Canagliflozin demonstrated unique renal outcome protection in CREDENCE, while ertugliflozin showed non-inferiority in VERTIS-CV without cardiovascular superiority [30].

vi. **Integration with Other Therapies:** Combination therapy with renin–angiotensin–aldosterone system (RAAS) blockers enhances renal protection, while SGLT2i plus glucagon-like peptide-1 receptor agonists (GLP-1 RA) provide complementary cardiovascular benefits [31]. Trials such as AMPLITUDE-O support additive effects when combining GLP-1 RAs with SGLT2i [32]. Emerging studies evaluate triple therapy with mineralocorticoid receptor antagonists, aiming to further slow CKD progression [33].

vii. **Mechanistic Insights: Beyond Glucose Lowering:** Preclinical studies reveal reductions in oxidative stress, inflammation, and renal fibrosis with SGLT2i [34]. Animal models show decreased renal NLRP3 inflammasome activation and attenuation of profibrotic cytokines [35]. Human studies demonstrate improved hematocrit and erythropoietin levels, potentially contributing to cardiovascular benefits [36].

viii. **Real-World Evidence:** Observational studies confirm trial findings. The CVD-REAL registry, involving over 300,000 patients, reported a 39% reduction in heart failure hospitalization and 51% reduction in all-

cause mortality with SGLT2i use compared with other glucose-lowering drugs [37]. Real-world effectiveness extends across diverse ethnic and age groups [38].

Future Directions and Clinical Implications

Future research should focus on precision medicine, identifying biomarkers predicting differential response to SGLT2i. Expanded indications in non-diabetic heart failure and CKD populations are already reshaping clinical guidelines [39]. Artificial intelligence–driven analyses of real-world datasets may refine patient selection and optimize outcomes [40].

Cost-effectiveness studies indicate long-term savings due to reduced hospitalizations and slowed CKD progression [41]. However, global access disparities persist, particularly in low- and middle-income regions where diabetes and CKD burden is rising rapidly [42]. Efforts to expand access will be critical for global health impact.

CONCLUSION

SGLT2 inhibitors have redefined the therapeutic paradigm in type 2 diabetes by providing dual benefits of renal protection and cardiovascular risk reduction. Robust evidence from randomized controlled trials and real-world studies demonstrates significant reductions in CKD progression, heart failure hospitalization, and cardiovascular mortality. These benefits are mediated through mechanisms beyond glucose lowering, including hemodynamic effects, improved myocardial energetics, reduced renal hypoxia, and anti-inflammatory actions. The safety profile is favorable, with most adverse events being mild and manageable. Rare risks such as euglycemic DKA underscore the importance of patient education and monitoring. Integration with established therapies, including RAAS blockade and GLP-1 receptor agonists, offers synergistic cardiorenal protection. Looking ahead, precision medicine, novel combinations, and broader applications in non-diabetic kidney and heart disease populations will expand the therapeutic relevance of SGLT2i. Ensuring equitable global access will be critical for maximizing their public health impact. Clinicians should prioritize SGLT2 inhibitors in type 2 diabetes patients with cardiorenal risk to optimize long-term outcomes.

REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels: IDF; 2021.
2. Einarson, T.R., Acs, A., Ludwig, C., Panton, U.H. Prevalence of cardiovascular disease in type 2 diabetes: a systematic review. Cardiovasc Diabetol. 2018;17:83. doi:10.1186/s12933-018-0728-6
3. Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572. doi:10.1056/NEJMoa0802987
4. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. doi:10.1056/NEJMoa1504720
5. Perkovic, V., Jardine, M.J., Neal, B., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306. doi:10.1056/NEJMoa1811744
6. Ugwu, O.P.C., Kungu, E., Inyangat, R., et al. Exploring indigenous medicinal plants for managing diabetes mellitus in Uganda. INOSR Exp Sci. 2023;12(2):214–224. doi:10.59298/INOSRES/2023/2.17.1000
7. Krishnamoorthy, R., Gatasheh, M.K., et al. Protective role of Jimson Weed in mitigating dyslipidemia, cardiovascular, and renal dysfunction in diabetic rats. Nat Prod Commun. 2024;19(12). doi:10.1177/1934578X241299279
8. Uti, D.E., Atangwho, I.J., Alum, E.U., et al. Natural antidiabetic agents: evidence and development pathways. Nat Prod Commun. 2025;20(3). doi:10.1177/1934578X251323393
9. Abdul-Ghani, M.A., Norton, L., DeFronzo, R.A. Role of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes. Endocr Rev. 2011;32:515–531. doi:10.1210/er.2010-0029
10. Devineni, D., Polidori, D. Clinical pharmacokinetics of SGLT2 inhibitors. Clin Pharmacokinet. 2015;54:1025–1041. doi:10.1007/s40262-015-0288-5
11. Heerspink, H.J.L., Perkins, B.A., Fitchett, D.H., et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation. 2016;134:752–772. doi:10.1161/CIRCULATIONAHA.116.021887
12. Baker, W.L., Smyth, L.R., Riche, D.M., et al. Effects of sodium-glucose cotransporter 2 inhibitors on blood pressure. J Am Soc Hypertens. 2014;8:262–275. doi:10.1016/j.jash.2014.01.007
13. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and kidney outcomes. N Engl J Med. 2016;375:323–334. doi:10.1056/NEJMoa1515920
14. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657. doi:10.1056/NEJMoa1611925
15. Perkovic, V., Jardine, M.J., Neal, B., et al. CREDENCE trial. N Engl J Med. 2019;380:2295–2306. doi:10.1056/NEJMoa1811744
16. Heerspink, H.J.L., Stefansson, B.V., Correa-Rotter, R., et al. DAPA-CKD trial. N Engl J Med. 2020;383:1436–1446. doi:10.1056/NEJMoa2024816

17. Cherney, D.Z.I., Dekkers, C.C.J., Barbour, S.J., et al. Mechanisms of renal protection with SGLT2 inhibition. Nat Rev Nephrol. 2020;16:497–514. doi:10.1038/s41581-020-0293-5
18. Vallon, V., Thomson, S.C. Targeting renal oxygenation with SGLT2 inhibitors. Diabetes Obes Metab. 2017;19:1801–1806. doi:10.1111/dom.13126
19. Zinman, B., Wanner, C., Lachin, J.M., et al. EMPA-REG OUTCOME. N Engl J Med. 2015;373:2117–2128. doi:10.1056/NEJMoa1504720
20. Neal, B., Perkovic, V., Mahaffey, K.W., et al. CANVAS. N Engl J Med. 2017;377:644–657. doi:10.1056/NEJMoa1611925
21. Wiviott, S.D., Raz, I., Bonaca, M.P., et al. DECLARE–TIMI 58. N Engl J Med. 2019;380:347–357. doi:10.1056/NEJMoa1812389
22. Zelniker, T.A., Wiviott, S.D., Raz, I., et al. SGLT2 inhibitors and heart failure. Lancet. 2019;393:31–39. doi:10.1016/S0140-6736(18)32590-X
23. McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., et al. DAPA-HF. N Engl J Med. 2019;381:1995–2008. doi:10.1056/NEJMoa1911303
24. Verma, S., McMurray, J.J.V. SGLT2 inhibitors and mechanisms of benefit. Nat Rev Cardiol. 2018;15:494–507. doi:10.1038/s41569-018-0037-5
25. Puckrin, R., Saltiel, M.P., Reynier, P., Azoulay, L., Yu, O.H.Y., Filion, K.B. SGLT2 inhibitors and risk of genital infections. Diabetes Obes Metab. 2018;20:740–748. doi:10.1111/dom.13120
26. Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B. Euglycemic DKA with SGLT2 inhibitors. Diabetes Care. 2015;38:1687–1693. doi:10.2337/dc15-0843
27. Watts, N.B., Bilezikian, J.P., Usiskin, K., et al. Canagliflozin and fracture risk. J Clin Endocrinol Metab. 2016;101:157–166. doi:10.1210/jc.2015-3167
28. Fitchett, D., Inzucchi, S.E., Cannon, C.P., et al. Long-term safety of SGLT2 inhibitors. Circulation. 2019;139:2022–2031. doi:10.1161/CIRCULATIONAHA.119.040130
29. McDonagh, T.A., Metra, M., Adamo, M., et al. ESC guidelines on heart failure. Eur Heart J. 2021;42:3599–3726. doi:10.1093/eurheartj/ehab368
30. Cannon, C.P., Pratley, R., Dagogo-Jack, S., et al. VERTIS-CV. N Engl J Med. 2020;383:1425–1435. doi:10.1056/NEJMoa2004967
31. Husain, M., Birkenfeld, A.L., Donsmark, M., et al. Combination GLP-1 RA and SGLT2i. Lancet Diabetes Endocrinol. 2019;7:776–785. doi:10.1016/S2213-8587(19)30249-9
32. Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., et al. AMPLITUDE-O. N Engl J Med. 2021;385:1522–1534. doi:10.1056/NEJMoa2108269
33. Bakris, G.L., Agarwal, R., Anker, S.D., et al. FIDELIO-DKD. N Engl J Med. 2020;383:2219–2229. doi:10.1056/NEJMoa2025845
34. Lim, V.G., Bell, R.M., Arjun, S., et al. SGLT2 inhibition reduces myocardial oxidative stress. Cardiovasc Res. 2019;115:1189–1200. doi:10.1093/cvr/cvy299
35. Leng, W., Ouyang, X., Lei, X., et al. SGLT2i and NLRP3 inflammasome suppression. Nat Commun. 2016;7:13009. doi:10.1038/ncomms13009
36. Sano, M., Goto, S.. Increased hematocrit and erythropoietin with SGLT2i. Circ J. 2019;83:182–188. doi:10.1253/circj.CJ-18-1242
37. Kosiborod, M., Lam, C.S.P., Kohsaka, S., et al. CVD-REAL. Circulation. 2017;136:249–259. doi:10.1161/CIRCULATIONAHA.117.029190
38. Birkeland, K.I., Jørgensen, M.E., Carstensen, B., et al. Real-world cardiovascular outcomes with SGLT2i. Lancet. 2017;390:2195–2203. doi:10.1016/S0140-6736(17)32232-3
39. Packer, M., Anker, S.D., Butler, J., et al. EMPEROR-Reduced. N Engl J Med. 2020;383:1413–1424. doi:10.1056/NEJMoa2022190
40. Ahmad, T., Lund, L.H., Rao, P., et al. Artificial intelligence and SGLT2 inhibitors. Eur J Heart Fail. 2021;23:893–896. doi:10.1002/ejhf.2181
41. McEwan, P., Darlington, O., McMurray, J.J.V., et al. Cost-effectiveness of SGLT2 inhibitors. Eur J Heart Fail. 2020;22:210–219. doi:10.1002/ejhf.1720
42. Bommer, C., Heesemann, E., Sagalova, V., et al. The global economic burden of diabetes. Lancet Diabetes Endocrinol. 2017;5:423–430. doi:10.1016/S2213-8587(17)30097-9

CITE AS: Niwarinda Arnold (2025). SGLT2 Inhibitors in Type 2 Diabetes Management: Renal Protection and Cardiovascular Outcomes. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(3):33-36. https://doi.org/10.59298/IDOSRJSR/2024/10.3.3336